Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose AmBisome versus amphotericin B deoxycholate for induction therapy of HIV-associated cryptococcal meningitis in sub-Saharan Africa
ISRCTN72509687Phase 3Completed
- Sponsor
- London School of Hygiene & Tropical Medicine
- Start
- Sep 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of amphotericin b, amphotericin b deoxycholate and fluconazole in cryptococcal meningitis (2 arms), sponsored by London School of Hygiene & Tropical Medicine. Primary endpoint: All-cause mortality within 10 weeks after randomization. Started Sep 2017; status: completed.
02
Drugs
amphotericin bamphotericin b deoxycholatefluconazole
03
Conditions
cryptococcal meningitis
Beyond the preview
Go deeper on ISRCTN72509687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN72509687.